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Abstract
Rationale The endocannabinoid (eCB) system is implicated
in several psychiatric disorders. Investigating emotional–
motivational dysfunctions as underlying mechanisms, a
study in humans revealed that in the C385A polymorphism
of the fatty acid amide hydrolase (FAAH), the degrading
enzyme of the eCB anandamide (AEA), A carriers, who are
characterized by increased signaling of AEA as compared to
C/C carriers, exhibited reduced brain reactivity towards
unpleasant faces and enhanced reactivity towards reward.
However, the association of eCB system with emotional–
motivational reactivity is complex and bidirectional due to
upcoming compensatory processes.
Objectives Therefore, we further investigated the rela-
tionship of the FAAH polymorphism and emotional–
motivational reactivity in humans.
Methods We assessed the affect-modulated startle, and rat-
ings of valence and arousal in response to higher arousing
pleasant, neutral, and unpleasant pictures in 67 FAAH
C385A C/C carriers and 45 A carriers.
Results Contrarily to the previous functional MRI study, A
carriers compared to C/C carriers exhibited an increased
startle potentiation and therefore emotional responsiveness
towards unpleasant picture stimuli and reduced startle inhi-
bition indicating reduced emotional reactivity in response to
pleasant pictures, while both groups did not differ in ratings
of arousal and valence.
Conclusions Our findings emphasize the bidirectionality
and thorough examination of the eCB system’s impact on
emotional reactivity as a central endophenotype underlying
various psychiatric disorders.
Keywords FAAH . Genetics . Endocannabinoid . Emotion .
Startle reflex
Introduction
The endocannabinoid (eCB) system is associated with
psychiatric disorders which are marked by emotional–
motivational dysfunction, e.g., anxiety, addiction, eating
disorders, and depression (Davis 2008; Monteleone et
al. 2009; Parolaro et al. 2010; Sipe et al. 2002), and it
constitutes an important research topic in relation to
psychiatric disorders (Lutz 2009).
The impact of the eCB system on emotional behavior is
very likely due to the central role of the eCB anandamide
(AEA). Like the phytocannabinoid Δ9-tetrahydrocannabi-
nol, AEA activates the cannabinoid type 1 (CB1) receptor as
the most important binding sites in brain regions involved in
regulation of emotions (Mackie 2005). AEA is degraded by
the enzyme fatty acid amide hydrolase (FAAH; Cravatt et al.
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1996), which also is a promising target for pharmacological
interventions in the treatment of the psychiatric disorders
mentioned above (Justinova et al. 2008; Monteleone et al.
2009; Schacht et al. 2009; Sipe et al. 2002). Accordingly,
FAAH should play a key role in AEA-mediated emotional
effects.
One recent seminal study (Hariri et al. 2009) tested the
assumed association of FAAH and emotional–motivational
reactivity in humans by investigating the influence of the
genetic FAAH C385A polymorphism on activity in the
brain’s emotion centers. The A allele variant of this poly-
morphism is associated with reduced levels of FAAH pro-
tein as compared to the C/C variant, as the A variant displays
normal catalytic properties, but an enhanced sensitivity to
proteolytic degradation (Chiang et al. 2004; Sipe et al.
2002), presumably leading to a shorter half-life time, and
thus to increased AEA signaling. The brain activities of A
and C/C carriers registered during a face allocation and a
gambling task were compared. In the face allocation task,
participants saw two faces (angry and fearful) and had to
indicate the one resembling a third target face; a comparable
task with shapes served as a control condition. In the gam-
bling task, participants had to indicate whether the value of a
card was higher or lower than 5 followed by positive or
negative feedback and the requirement to press a button
after the positive feedback. They had the possibility to win
money. This was compared to a control task, where alter-
nating button presses during the presentation of an “x”
which was followed by an asterisk and a yellow circle were
required. Results indicated for FAAH C385A A compared to
C/C carriers an enhanced reactivity of the ventral striatum in
the gambling task and a reduced reactivity of the amygdala
in the face allocation task (Hariri et al. 2009). Results seem
to indicate that FAAH A carriers are characterized by a
reduced reactivity towards threat and an increased reactivity
towards reward.
These results are in line with reports that disruption of
FAAH activity may have anxiolytic and antidepressant
effects mediated by CB1 receptor stimulation (Bortolato et
al. 2007; Kathuria et al. 2003; Moreira et al. 2008). Possibly,
anxiolytic effects by FAAH C385A are mediated by arousal,
which is increased in C/C carriers (Dlugos et al. 2010). In
addition, stimulation of the CB1 receptor by eCBs, e.g., by
decreasing FAAH enzymatic activity, has reinforcing effects
and can induce happiness, food intake, and drug seeking by
increasing dopamine activity in the nucleus accumbens
(Basavarajappa et al. 2006; Mahler et al. 2007; Pagotto et
al. 2006; Solinas et al. 2007; Tanda and Goldberg 2003).
Furthermore, using functional MRI (fMRI) in humans, can-
nabinoids were found to reduce amygdala reactivity towards
threat (Phan et al. 2008).
However, even though the study of Hariri et al.
(2009) has importantly advanced our knowledge about
FAAH-modulated brain responses triggered by emotion-
al–motivational stimuli, further studies are needed for
several reasons. First, Hariri et al. (2009) examined
FAAH-modulated brain reactivity in response to emo-
tional salient stimuli which were part of specific tasks;
thus, FAAH effects on the “pure” processing of emo-
tional stimuli independent of other cognitive processes
need to be examined. Second, Hariri et al. (2009) ex-
amined responses to specific low-arousing stimuli, i.e.,
faces expressing anger and threat or stimuli signaling
positive and negative feedback, although emotional
stimuli may vary on a valence dimension from pleasant
to unpleasant and also with respect to arousal values.
Third, the eCB system’s involvement in emotional pro-
cessing is very complex and also bidirectional (Moreira
and Lutz 2008), which requires further studies to this
theme using various stimuli and study conditions. Final-
ly, it seems desirable to complement the work of Hariri
et al. (2009) on FAAH C385A polymorphism and emo-
tional–motivational reactivity by further experiments us-
ing behavioral measures of emotional reactivity; fMRI
measures involve methodological concerns including
baseline problems (Canli and Lesch 2007) and a lack
of validated animal models. Further studies warranted
aim at using measures of emotional reactivity which
allow translational research necessary to unravel the
neurochemical pathway underlying the eCB effects on
emotions, and in further perspectives to address clinical
pharmacological questions of treatment and prevention.
A behavioral measure directly indicating emotional reac-
tivity in animal and human is the affect-modulated startle
reflex. In humans, this reflex is assessed by the eye blink via
EMG at the M. orbicularis oculi elicited by a load abrupt
noise (Blumenthal et al. 2005). It is well known that the
defensive startle reflex is potentiated during the presentation
of unpleasant stimuli because of the engagement of the
defensive system. On the other hand, the startle reflex is
attenuated during pleasant stimuli because of the mismatch
between the defensive reflex and the engaged appetitive
system (Lang 1995). Addiction and anxiety disorders were
observed to be related to specific abnormalities in startle
reflex modulation (Grillon and Baas 2003).
Accordingly, the aim of this study was to further inves-
tigate the influence of the FAAH C385A polymorphism on
emotional–motivational reactivity using a translational be-
havioral measure, the affect-modulated startle reflex, which
was assessed during the presentation of pleasant, neutral,
and unpleasant International Affective Picture System
(IAPS) pictures (Lang et al. 2005). Based on the study by
Hariri et al. (2009), A allele carriers were expected to show a
reduced reactivity towards unpleasant stimuli and an in-
creased reactivity towards pleasant stimuli as compared to
C/C carriers.
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Materials and methods
Participants
Data of 112 adult participants from the general population
were analyzed (67 FAAH C385A C/C carriers and 45 A car-
riers). Originally, the sample consisted of 119 participants.
However, seven participants had to be excluded as startle
nonresponders (seven C/C carriers and two A carriers; devia-
tion of the number of startle zero reactions of more than 2.5
standard deviations of the sample’s mean). A further descrip-
tion of the sample can be found in the “Results” section.
All participants were recruited via newspaper advertise-
ment. After a telephone screening ensuring the absence of
current or lifetime psychiatric disorders or severe somatic
disorders, participants completed a diagnostic interview for
psychiatric disorders [Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I) and SCID II (First
1996; First et al. 1997)]. Only participants free of any
lifetime or present psychiatric diagnoses and free from cur-
rent drug or alcohol consumption were recruited. Further
exclusion criteria were the age under 18 and over 60 years,
IQ level below 80 [MWT-B (Lehrl 1989)], severe somatic
disorders, hearing problems, and psychotropic medication.
Written informed consent, according to the guidelines of the
ethical committee in Würzburg and the ethical standards laid
down in the 1964 Declaration of Helsinki, was provided by
all participants.
Genotyping
DNA has been extracted from peripheral blood by a
routine desalting method. rs324420 has been determined
by standard polymerase chain reaction. The following
primers were used to amplify a region of 333 bp: F:5′-
TGTTGCTGGTTACCCCTCTC-3′ and R:3′-AATGAC
CCAAGATGCAGAGC-5′. The PCR reaction mix (25 μl)
consisted of 10× Goldstar mix (2.5 μl), 15 mM MgCl2
(1 μl), 2.5 mM of each nucleotide (1 μl), 1 μl of each primer,
0.2 μl Taq Polymerase, 18.3 μl of ddH2O, and 1 μl DNA
template. Cycling conditions were 95 °C denaturation at
5 min, then 35 cycles of 45 s at 95 °C/45 s at 58.8 °C/45 s at
72 °C. The final step was 5 min at 72 °C. PCR product was
digested at 37 °C with STYI (New England Biolabs, Beverly,
MA, USA) which cuts the amplicon in the presence of the
ancestral C allele in fragments of 200 and 133 bp. Fragments
were visualized on an agarose gel stained with ethidium
bromide.
Procedure
The experimental procedures were controlled by Experimen-
tal Run Time System (version 3.32, BeriSoft Cooperation,
Frankfurt, Germany). The study began with a familiarization
to the experimental protocol by presenting two pleasant, two
neutral, and two unpleasant pictures from the IAPS (Lang et
al. 2005); all picture numbers can be found in Electronic
supplementary material 1) with startle tones (50 ms of 95-dB
white noise with an instantaneous rise time presented binau-
rally with Beyerdynamic DT 331 headphones, Heilbronn,
Germany) presented during one picture of each valence cate-
gory. During the experiment proper, 18 pleasant, 18 neutral,
and 18 unpleasant IAPS pictures were presented together with
startle tones; 18 additional pictures, six of each valence cate-
gory, were used as fillers. Pictures were shown for 8 s with an
inter-trial interval (ITI) of 16.5–25.5 s. The startle tones were
administered 2.5, 4.0, or 5.5 s after picture onset. Eighteen
additional startle tones during the ITIs were delivered to
measure baseline startle responses and startle habituation.
Startle stimuli were displayed on the background of a constant
60-dB white background noise (white noise generator Lafay-
ette Instruments Co., Lafayette, IN). To ensure comparable
valence and arousal levels, some pictures were different for
men and women (81 % were exactly the same or were
matched for content). For females and males, three pseudo-
randomized picture orders with not more than two consecutive
pictures of the same valence or the same startle onset time
were generated. After the startle assessment, pictures were
presented again in a free-viewing condition, and participants
rated the pictures’ valence and arousal using nine-point Self-
Assessment Manikin scales (Lang 1980).
Physiological recordings
EMG was measured from the left M. orbicularis occuli with a
Vitaport II system (Becker Meditec, Karlsruhe, Germany;
512 Hz with online high- and low-pass filters of 0.015 s and
2,200 Hz). The signals were rectified, integrated, stored at
256 Hz, and later smoothed offline (using a time constant of
100 ms) and analyzed by one experienced expert blind to
genetic condition using Matlab (The MathWorks, München,
Germany). Startle magnitude was the difference between the
peaks in a time window of 19.5–151.5 ms after the onset of the
startle toneminus the baseline asmeanEMGover 19.5 s before
the startle stimulus. Trials with baseline shifts from 19.5 ms
before to 15.6 ms after the startle probewere excluded from the
analysis. Trials with no detectable peak were scored as zero.
Data analyses
Sociodemographic data were evaluated with one-way
ANOVAswith genotype (FAAHC385AC/C carrier and FAAH
C385A A carrier) and sex as between-subjects factors, or with
χ2 tests. For affect-modulated startle response as well as
valence and arousal ratings, means were calculated for each
valence condition (pleasant, neutral, and unpleasant; for startle
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data, means were built over all startle onsets per valence
condition1). These means were then entered into repeated-
measures ANOVAs with genotype and sex as between-
subjects factors and picture valence (pleasant, neutral, and
unpleasant) as a within-subjects factor. Startle habituation
was analyzed with a repeated-measures ANOVA with geno-
type and sex as between-subjects factors and time of measure-
ment (T1 to T6; each as mean over three consecutive ITI
startle stimuli) as a within-subjects factor. Sex was included
in all analyses to control for genotype x sex effects. However,
sex never had an impact, and sex effects are therefore not
reported. Greenhouse–Geisser corrections were used if appro-




FAAHC385A allele frequencies were 0.78 for C and 0.22 for
A. The genotype distribution (C/C067, C/A040, and A/A0
5) was in accordance with the Hardy–Weinberg equilibrium
(χ200.1, n.s.). There were no differences between the FAAH
C385A A variant and C/C variant in sex distribution (χ2(1)0
0.3, p00.264), age, IQ, trait anxiety, impulsivity, empathy,
or venturesomeness (all Fs<2.1, ps>0.145; see Table 1).
Picture ratings
Mean picture ratings stratified for the gene variants can be
derived from Table 1. ANOVAs indicated significant effects
for the valence [F(2, 216)01,428.0, p<0.001] and the arous-
al [F(2, 216)0404.0, p<0.001] ratings. The valence rating
increased from unpleasant to neutral to pleasant pictures (all
ts(111)>22.6, ps<0.001; mean±SD, pleasant, 7.1±0.7; neu-
tral, 5.4±0.8; unpleasant, 2.6±0.7). The arousal was rated
higher for emotional compared to neutral, and for unpleas-
ant compared to pleasant pictures (all ts(111)>12.4, ps<
0.001; mean±SD, pleasant, 5.0±1.1; neutral, 3.7±1.0; un-
pleasant, 6.6±0.9). There were no effects of genotype or
genotype×valence [all Fs<1.6, ps>0.198].
Startle modulation
The ANOVA for the affect-modulated startle data revealed a
main effect of valence [F(2, 216)022.2, p<0.001], which
was due to increasing startle responses from pleasant to
neutral to unpleasant pictures (all ts(111)>3.0, ps<0.004).
There was no main effect for genotype [F(1, 108)00.1, p0
0.772], but a genotype×valence interaction [F(2, 216)03.9,
p00.024] (Fig. 1). The genotype×valence interaction was
further analyzed by comparing groups regarding startle in-
hibition by pleasant pictures and startle potentiation by
unpleasant pictures (difference emotional minus neutral
stimuli). This ANOVA revealed a significant genotype main
effect [F(1, 110)06.9, p00.010], indicating that A carriers as
compared to C/C exhibited enhanced startle potentiation for
unpleasant pictures and reduced startle inhibition for pleas-
ant pictures; the genotype×valence interaction was not sig-
nificant [F(1, 110)02.2, p00.145]. T tests against zero
demonstrated that startle potentiation was significant for A
[t(44)04.2, p<0.001] but not C/C carriers [t(61)01.1, p0
0.568], while startle inhibition was significant for C/C [t
(61)0−3.0, p00.012] but not A carriers [t(44)0−0.8, p0
0.434].2
The ANOVA for the ITI startle baseline and its habitua-
tion revealed a significant main effect of time [F(5, 540)0
53.4, p<0.001], indicating that the startle responses declined
during the experiment (all ts>3.0, ps<0.012; except for T30
T4 and T50T6, ts<2.1, ps>0.084; mean±SD, T1010.2±7.5,
T208.5±7.3, T306.6±5.9, T406.4±6.0, T505.4±5.2, T60
4.8±5.1). Neither the genotype main effect nor the genotype×
time interaction was significant [all F<0.5, ps>0.486].
Discussion
This study, to our knowledge, is the second directly assess-
ing the association of the FAAH polymorphism (C385A)
with emotional–motivational responses in humans. The pre-
ceding study by Hariri et al. (2009) revealed in FAAH
C385A A as compared to C/C carriers reduced amygdala
reactivity during a face allocation task involving fearful and
angry faces and an increased ventral striatum reactivity in a
gambling task with positive and negative feedback and the
possibility to win money. We wished to provide new data
demonstrating effects of the FAAH C385A polymorphism on
the engagement of the defensive and appetitive motivational
systems towards stimuli from the IAPS varying on the
valence dimension from pleasant over neutral to unpleasant,
as reflected in behavioral measure, i.e., startle response
potentiation and inhibition, respectively.
1 There was no influence of startle onset on valence or genotype
effects. This was verified by an additional ANOVA including startle
onset as additional within-subjects factor together with valence, sex,
and genotype. The valence and genotype x valence effects remained
(Fs>3.6, ps<0.028), while all other effects including startle onset and
valence or genotype were not significant (Fs<2.0, ps>0.104).
2 To take measures of impulsiveness and trait anxiety into account,
both variables were entered as covariates into the overall ANOVA for
affect-modulated startle response. The genotype×valence interaction
remained significant [F(2, 212)03.9, p00.025]. In addition, we found
no correlations between startle potentiation and startle inhibition and
measures of anxiety and impulsiveness (all p>0.085).
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While self-reports of valence and arousal were not affected
by genotype, we observed in FAAH C385A A carriers as
compared toC/C carriers both an increased startle potentiation
indicating an increased reactivity towards unpleasant pictures,
as well as a reduced startle inhibition reflecting a reduced
reactivity towards pleasant pictures. These behavioral results
suggest enhanced amygdala and reduced ventral striatum
activity in FAAH C385A A compared to C/C carriers in re-
sponse to unpleasant or pleasant stimuli, respectively (see
Koch 1999). Accordingly, our results stand in contrast to the
only other study on this topic (Hariri et al. 2009).
Interestingly, there are studies supporting both directions
of how FAAH C385A may influence emotional–motivation-
al reactivity. While several studies on anxiolytic and rein-
forcing effects of FAAH disruption and increased eCB
signaling, respectively, are in accordance with the Hariri et
al. (2009) findings (e.g., Basavarajappa et al. 2006;
Bortolato et al. 2007; Kathuria et al. 2003; Mahler et al.
2007; Moreira et al. 2008; Pagotto et al. 2006; Solinas et al.
2007; Tanda and Goldberg 2003), some other studies ob-
served the opposite association in line with our results (e.g.,
Hall and Solowij 1998; Kalant 2004; Moreira et al. 2009;
Morrison et al. 2009; Trezza and Vanderschuren 2009).
It may be speculated that this bidirectionality is related to
the fact that a low activation of the eCB system and AEA
signaling have anxiolytic effects via CB1 receptor activa-
tion, while high activation increases anxiety and aversion by
binding of AEA to transient receptor potential vanilloid 1
channel triggering a downregulation of the eCB 2-
arachidonoyl glycerol (Kathuria et al. 2003; Maccarrone et
al. 2008; Moreira et al. 2008; Rubino et al. 2007, 2008;
Ruehle et al. 2012; Sañudo-Peña et al. 1997; Terzian et al.
2009; Viveros et al. 2005). While FAAH C385A A carriers
should be characterized by increased levels of the eCB AEA
as compared to C/C carriers (Chiang et al. 2004; Sipe et al.
2002), AEA levels should additionally depend on the inten-
sity of the emotional context (Marsicano et al. 2002). There-
fore, low-arousing contexts as used in the Hariri et al. (2009)
study (angry and fearful faces, Wieser et al. 2011) or reward
as part of possibly distracting cognitive–motor tasks) may
lead to anxiolytic effects, while high arousing stimuli (pleas-
ant, neutral, and unpleasant images of various contents and
without cognitive load) as used in the present study may
have anxiogenic effects. However, this speculation must be
experimentally tested in future studies using differentially
arousing emotional contexts, different assessment methods,
and if possible pharmacological receptor blockers.
Interestingly, both the present and the Hariri et al. (2009)
study observed that the association of the FAAH C385A
polymorphism with emotional responses was contrary for
unpleasant and pleasant stimuli. This suggests that the dif-
ferential effects of FAAH C385A on responsiveness towards




with the MWT-B (Lang 1980)
bStait Trait Anxiety Inventory
(Spielberger et al. 1970)
cI7 questionnaire (Eysenck et al.
1985)
dScales: valence, 10highly un-
pleasant, 90highly pleasant;
arousal, 10calm, 90excited
FAAH C385A A carriers FAAH C385A C/C carriers
Mean±SD or n Mean±SD or n
Sex (n women/n men) 27/18 33/34
Age 34.4±9.5 34.2±10.2
IQa 116.8±13.0 117.9±14.2
STAIb Trait Anxiety 33.0±6.7 33.3±8.9
I7c Impulsivity 5.1±2.8 6.0±3.1
I7c Empathy 13.9±3.4 13.9±3.0
I7c Venturesomeness 8.2±3.3 8.8±3.3
Valence/arousal ratingd
Pleasant pictures 7.2±0.7/5.0±1.1 7.0±0.7/5.0±1.0
Neutral pictures 5.4±0.8/3.8±1.0 5.3±0.7/3.6±1.1
Unpleasant pictures 2.6±0.8/6.6±1.0 2.6±0.7/6.6±0.9
Fig. 1 Means (±SE) for FAAHC385AA carriers (n045) and CC carriers
(n067) of affect-modulated startle inhibition during pleasant and startle
potentiation during unpleasant pictures (difference scores emotional–
neutral pictures)
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between the amygdala and the ventral striatum (Yim and
Mogenson 1982, 1989).
Of course, our study also has limitations. First, the study is
correlative and cannot deliver answers about the nature of the
association between FAAH C385A and emotional reactivity.
Second, comparably to the study of Hariri et al. (2009), the
polymorphism did not influence the verbally assessed pheno-
types, such as impulsivity, anxiety or valence, and arousal
ratings. However, ratings and verbal responses are much more
prone to be biased by normative behavior, expectancies, and
social requirements, and endophenotypes such as emotion
reactivity may be better revealed by biopsychological measures
(Castellanos and Tannock 2002). Third, we examined a truly
healthy sample on the basis of a thorough screening for any
psychopathology. Thus, we purposely decreased the variance
of the phenotype, and as a consequence, reduced the power to
detect genetic effects. Since Hariri et al. (2009) did not explic-
itly screen for psychopathology in the past, we have to assume
that their sample included some participants with at least life-
time axis I disorders. However, this difference in sample char-
acteristics very unlikely can explain the opposite findings.
The eCB system is involved in various psychiatric dis-
orders, such as mood disorders, addiction, pain, and anxiety
disorders (Monteleone et al. 2009; Parolaro et al. 2010; Sipe
et al. 2002). FAAH inhibitors are promising pharmacologi-
cal agents in the treatment of pain and anxiety without drug-
seeking side effects (Davis 2008). Accordingly, this study
contributes to an area of substantial interest for the devel-
opment of psychological and psychopharmacological treat-
ments and asks for further research to clarify the
bidirectionality of the eCB system’s influence on emotion
processing.
In summary, we believe to have assessed emotional re-
activity with an objective, reliable, and valid experimental
protocol. Startle responses were scored by one experienced
expert blind to the genetic conditions, and picture ratings as
well as general startle effects, such as the observed main
valence and habituation effects, are in accordance with a
multitude of previous studies. Therefore, our results justify a
new starting point for further research on the association
between the FAAH enzyme and the eCB neurotransmitter
system and emotional–motivational reactivity. We are far
away with our study from explaining the exact mechanism
of this association. However, we hope that we could indicate
that a one-sided view of this association is not sufficient,
and further research is needed.
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